ChemAbout

ChemAbout is a B2B platform where chemical buyers and suppliers discover each other.

Post a purchase requestList your products (for suppliers)
© 2026 ChemAbout
Compound Index|Demand Board|Insights|Exhibitions|Compliance|Help Center|Privacy Policy|Terms of Service|[email protected]
Home/Compounds/Pharmaceutical Intermediate/N-Fmoc-O-benzyl-L-phosphotyrosine
C31H28NO8P
573.5 g/mol
Pharmaceutical Intermediate

Fmoc-Tyr(HPO3Bzl)-OH

CAS191348-16-0
Category
Pharmaceutical Intermediate
Compound Class
Peptide
Primary Use
Pharmaceutical Intermediate

Fmoc-Tyr(HPO3Bzl)-OH is a phosphotyrosine building block used in solid-phase peptide synthesis. It contains a benzyl-protected phosphate group on the tyrosine side chain, enabling the incorporation of phosphorylated tyrosine residues into synthetic peptides for biochemical research.

Building block for solid-phase peptide synthesisReagent for phosphorylated peptide preparation

Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.

Sourcing Fmoc-Tyr(HPO3Bzl)-OH?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request→Supplier? List your product for this CAS→

Related Compounds

SimilarStructure SimilarSimilarity 0.73

Fmoc-O-(benzylphospho)-L-serine

CAS158171-14-3

research compound

ReferenceSame Category

1,2,3,4-Tetrahydro-1-naphthoic acid

CAS1914-65-4

pharmaceutical intermediate

ReferenceSame Category

Methyl 3,4,5-trimethoxybenzoate

CAS1916-07-0

pharmaceutical intermediate

ReferenceSame Category

3-Bromo-4-(trifluoromethoxy)aniline

CAS191602-54-7

pharmaceutical intermediate

ReferenceSame Category

Di-p-anisoyl-D-tartaric acid

CAS191605-10-4

pharmaceutical intermediate

Related Reading

Therapeutic Peptides in 2026: This Year's Breakthroughs

2026 has been a concentrated year for peptide therapeutics. Efficacy reached a new high in late-stage trials, the obesity field moved beyond the incretins to amylin, the oral route reached weight management, and peptide-guided radioligand therapy kept advancing — each point tied to a specific 2025–2026 result.

Read more
Identifiers
IUPAC Name

(2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-[4-[hydroxy(phenylmethoxy)phosphoryl]oxyphenyl]propanoic acid

InChIKey

WNFKGEXQEWKECX-LJAQVGFWSA-N

SMILES

C1=CC=C(C=C1)COP(=O)(O)OC2=CC=C(C=C2)C[C@@H](C(=O)O)NC(=O)OCC3C4=CC=CC=C4C5=CC=CC=C35

Synonyms (11)
  • Fmoc-L-Tyr(HPO3Bzl)-OH
  • Fmoc-Tyr(HPO3Bzl)-OH
  • fmoc-tyr(po(obzl)oh)-oh

Sourcing Fmoc-Tyr(HPO3Bzl)-OH?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request→Supplier? List your product for this CAS→